Folic acid use linked to lower diabetes risk in coronary heart disease study

A study published September 5, 2026 in Drug Design, Development and Therapy linked folic acid use to a lower rate of new diabetes in patients with coronary heart disease. This retrospective coverage examines a finding relevant to metabolic prevention, while separating the observed association from evidence that supplementation causes a benefit.

### What the researchers found

The multicenter observational analysis matched 488 folic acid users with 1,952 non-users. Participants did not have diabetes at baseline. Over a median 3.35 years, researchers recorded 510 new diabetes cases.

After matching and statistical adjustment, folic acid use was associated with a hazard ratio of 0.749 for new diabetes, with a 95% confidence interval of 0.586–0.957. The endpoint was incident diabetes; repeated HbA1c measurements also assessed blood-sugar trajectories.

Researchers classified users as patients who had taken folic acid continuously for at least six months before enrollment. They observed existing treatment patterns rather than randomly assigning supplementation. That distinction limits what the result can establish.

### Why matching does not settle causation

Propensity score matching aims to make treated and untreated groups more comparable using recorded characteristics. It is useful when researchers cannot assign treatment experimentally, but its ability to reduce bias depends on the information available and how the analysis is constructed.

As methodological work by statistician Peter Austin explains, propensity scores balance measured baseline characteristics. They cannot guarantee balance in factors that were never measured. Random allocation, by comparison, balances both measured and unmeasured characteristics on average.

Applied here, the key unanswered question is whether folic acid itself accounts for the difference or whether some characteristics associated with its use contribute. Matching strengthens an observational comparison without automatically turning it into a causal experiment.

The reported hazard ratio also should not be read as the percentage of individual patients who would avoid diabetes by starting a supplement. It describes a relative association over follow-up, within the population and statistical model studied. Translating that association into a treatment benefit requires stronger evidence.

### Biological plausibility has limits

Folate is a B vitamin involved in DNA synthesis and amino-acid metabolism. The National Institutes of Health Office of Dietary Supplements describes its role in converting homocysteine to methionine, a pathway that helps explain scientific interest in folate and vascular health.

But a nutrient’s biochemical role does not by itself establish that extra intake prevents chronic disease. NIH’s evidence summary illustrates the broader difficulty: folic acid can lower homocysteine, yet clinical outcomes require their own assessment. A change in a laboratory measure cannot substitute for evidence that people remain healthier.

Baseline nutritional circumstances matter as well. NIH reports that most people in the United States obtain adequate folate and that fortified foods contribute to intake. Evidence from one clinical population therefore needs careful assessment before being extended to people with different diets, health conditions or nutritional status.

### What would change the interpretation

The practical research question is whether a randomized prevention trial would reproduce the association while assessing adverse effects and clinically meaningful outcomes. Such a trial would help distinguish a supplement effect from differences between people who already use it and those who do not.

For healthspan reporting, the relevant standard is prevention of disease and preservation of function. This finding supports further investigation; it does not establish folic acid supplementation as a diabetes-prevention strategy or demonstrate longer, healthier life.